First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
Recruiting · NCT05374278 · Registry updated 2025-04-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia | Alzheimer disease, Frontotemporal Lobar Degeneration, Nutritional and Metabolic Diseases, TDP-43 proteinopathy, brain disorder, central nervous system disorder, cognitive disorder, dementia, frontotemporal dementia, metabolic disease, nervous system disorder, neurodegenerative disease, proteostasis deficiencies, psychiatric disorder, tauopathy | Recruiting | Phase 1 / Phase 2 | 2025-04-17 | NCT05374278 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| David Wilson | 1 |
| Rio pharmaceuticals Inc. | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| China Basin, UCSF | San Francisco | United States | 1 |